Status:
COMPLETED
A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Myelofibrosis
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to evaluate the long-term effects of orally administered SAR302503 (TG101348) in patients with myelofibrosis who have completed the MF-TG101348-001 study.
Detailed Description
SAR302503 (TG101348) is a potent small molecule inhibitor of Janus kinase 2 (JAK2). This is an extension study for a first-in-man, dose escalation study (MF-TG101348-001). The safety, tolerability and...
Eligibility Criteria
Inclusion
- Completion of MF-TG101348-001 study
- Diagnosis of myelofibrosis
- At least 18 years of age
Exclusion
- Any acute or chronic medical abnormality that may increase the risk associated with study participation
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2014
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00724334
Start Date
July 1 2008
End Date
May 1 2014
Last Update
March 5 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigational Site Number 840103
La Jolla, California, United States, 92093
2
Investigational Site Number 840102
Stanford, California, United States, 94305
3
Investigational Site Number 840105
Boston, Massachusetts, United States, 02115
4
Investigational Site Number 840106
Ann Arbor, Michigan, United States, 48109-0759